logo
episode-header-image
Feb 2024
33m 54s

The Big Business Behind Weight Loss Drug...

CNN
About this episode
It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sanjay Gupta turns to his CNN colleague Meg Tirrell for answers, and a little cont ... Show More
Up next
Aug 21
Revisiting: Why You're Breathing Wrong, and How to Fix It
Chronic disease, anxiety, ADHD, and even the shape of a person's face could be consequences of dysfunctional breathing. And most of us, it turns out, are doing it wrong – but it’s never too late to fix it. Sanjay sits down with journalist James Nestor to discuss the fifth anniver ... Show More
30m 16s
Aug 14
Revisiting: Relax, Jealousy is Normal
No, you’re not petty for feeling jealous. Research shows humans experience this emotion even before they can crawl. CNN chief medical correspondent Dr. Sanjay Gupta sits down with psychologist Dr. Joli Hamilton to demystify jealousy and why the complex emotion is not only natural ... Show More
28m 57s
Aug 7
Your Checklist for Medical Care Abroad
More Americans are traveling abroad for medical care. Sanjay talks with Harvard Law professor Glenn Cohen about vetting providers, understanding risks and asking the right questions, plus a practical checklist for navigating the process. Harvard Law Bulletin, “Patient Without Bor ... Show More
30m 33s
Recommended Episodes
Jun 2024
The weight-loss drug revolution
Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ... Show More
17m 28s
Mar 2025
The State of Weight-Loss Drugs
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big- ... Show More
30m 7s
Jul 2023
How Drugs Like Ozempic Are Changing What We Think About Weight Loss
You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of ... Show More
28m 5s
Jul 2023
One Thing: Weight Loss Drugs: Trend or Treatment?
A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ... Show More
17m 14s
Dec 2024
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More
11m 16s
Dec 2024
Deep Dive: The Gold Rush to Cure the Obesity Epidemic
<p>GLP-1 weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound, are credited with reversing obesity trends in the U.S. for the first time in decades, according to a new study in the Journal of the American Medical Association. The episode highlights the rapid ... Show More
8m 47s
Aug 2021
Weight loss supplements: how hype triumphs over substance
Weight loss supplements are big business. Fat burners, fat blockers, metabolism boosters, appetite suppressants – these are just some of the popular kinds of pills, potions and herbal concoctions that fly off pharmacy and health food store shelves. But how effective are any of th ... Show More
12m 31s